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When renal transplantation became a practical means of therapy 
Jlmost two decades ago, I diabetes melIirus was considered a high 
r:sk factor, which precluded candidacy, except when related donors 
were available. Najarian et aI. 2 popularized renal"transplantation in 
diabetics, provided evidence that patient survival was superior to 
that with chronic dialysis, and emphasized the necessity for an 
inter~isciplinary health care team before and after transplantation. 
In an exhaustive report covering a lO-year period, Najarian et 
al. 2 provided a follow-up for 109 diabetic patients who underwent 
primary cadaveric renal transplantation under treatment with 
azathioprine, prednisone, and antilymphocyte globulin (ALG). 
;!.e one-year cadaveric graft survival of 60% was a high water 
mark, marred only by the patient mortality which was 30% in the 
flfst post-operative year. Discussions of Najarian's paper by 
several transplantation surgeons made it clear that others were not 
achieving even this level of success.! 
The unsatisfactory results with cadaveric transplantation in 
diabetic, (or for that matter non~abeticFI patients has been a 
nagging indictment of the deficiencies of the techniques of 
immunosuppression, which have changed little since the mid-
1960's. Treatment in most centers has been with the double drug 
combination of azathioprine-prednisone,"3 and in almost all of the 
rest, triple drug therapy with azathioprine, prednisone, and anti-
lymphocyte globulin (ALG) has been used. l " With either 
approach, high~ose chronic therapy with steroids has been an 
unusually adverse factor for diabetics, with a predictable increase 
in insulin needs, and with a high incidence of infections and 
vascular complications. 
Minor variations from basic double and triple drug therapy have 
been reviewed. l These did not have a major impact. Other attempts 
to improve the outlook have been with tissue typing,6.1 and with 
systematic preoperative blood transfusion of the recipient.' 
With the introduction by Caine et aI. 9,10 of the new drug, 
cyclosporine, as a single immunosuppressive agent, or with the use 
of cyclosporine plus a limited quantity of steroids as we have 
recOlrunended,ll.12 there has been the prospect of better graft sur-
vival with less morbidity. To see if this objective has been realized, 
we report here the fate of diabetic patients during our early expe-
rience with cyclosporine-steroid therapy. For comparison. a small 
group of patients given azathioprine and steroids during the same 
time will be included. 
METHODS 
The cases were divided into three groups. There were three type 
I diabetics treated during pilot trials with cyclosporine and steroids 
in 1980 (Group 1); follow-ups are available of 21h to 3 years (Table 
1). In 1981, seven type I diabetics were given cyclosporine and 
steroids (Group 2), most during participation in a randomized trial 
which included seven other patients (Group 3) treated with azathio-
prine and steroids (Table 1), 
All of the patients treated with azathioprine and prednisone 
(Group 3) were undergoing transplantation for the first time. 
whereas one of the 10 treated with cyclosporine (Groups 1 and 2) 
had rejected a primary kidney under conventional therapy, and was 
undergoing retransplantation (Table 1). The features of the three 
groups are summarized in Table I. The patients were reasonably 
matched for age, lack of good typing at the A and B loci, and 
transfusion history, but with a slight advantage for the azathioprine-
steroid group (Table 1), Matching at the DR locus was random, The 
Table I. 
Type I Diabetics Receiving Cadaveric Kidneys 1980 -1981 (Data, Mean ± SO) 
No. of No. pJimary Matches 2:3 Preop Patient Followup 
Group Patients Grafts Age Transplantation A, B Loci Transfusions (Months) 
1 
Cyclosporine-Steroids 3 3 44 ± 2 3/3 0.33 ± 0.57 0/3 33.3 ± 2.9 
(Pilot) 
2 
Cyclosporine-Steroids 7 S" 40.6 ± 10.S 617 1.57 ± 1.39 3/7 15.7 ± 2.9 
(Randomized) 
3 
Azathioprine-Steroids 7 S" 36.9 ± 6,2 717 2.00 ± 1.52 5/7 19.7 ± 2.9 
(Randomized) 
• One of the kidneys in each group was transplanted in 1982 after loss of a graft transplanted in 1981. 
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---DR matches were obtained after the transplamations had been 
completed. and were uniformly poor. 
Azathioprine and prednisone were used together in the standard 
way, I beginning high dose steroid therapy at 200 mg on the day of 
operation. with subsequent gradual weaning. In Groups I and 2, 
cyclosporine was begun at I7 mg/Kg/day, and prednisone was 
begun at 200 mg, with daily decrements of 40 mg until a main-
tenance dose of 20 mg/day was reached in adults after 5 days. 
Further adjustments in cyclosporine or steroid doses were as 
previously described. 11·1) 
RESULTS 
Patient Survival 
All 17 patients are alive with follow-ups of one to three years. 
Graft Survival 
Group One 
All three of the cadaveric grafts in this pilot trial are still 
functioning after 21h to 3 years. Tho of the three patients have 
normal renal function. The third had nearly normal graft function 
for 21h years, but developed an elevation of creatinine to 3.6 mg% 
when maintenance steroid therapy was reduced from 10 to O/mg/ 
day. The deterioration was reversed after return to low dose steroid 
therapy . 
Group Two 
Six of the seven recipients achieved chronic survival of their 
grafts (Table m. Through a blood typing error, the seventh patient 
who was of 0 blood type was given an A kidney, which underwent--
Table II. 
Graft Survival, Blindness and Amputations 
Patients 
Survival Survival of Patients Legally 
1980-1981 Subsequent Dialysis Blind Post-Op 
Group Grafts Grafts Free Preop Amputations 
1 3/3 3/3 1/3 3/3 
2 6/7 1 "/1 7/7 2/7 1/7 
3 5/7 1 "/1 6/7 117 3/7 
Total 14/17 212 16/17 4117 7/17 
·Subsequent grafts were placed in 1982 under cyclosporine-steroid 
therapy with present follow-ups of 9 (the patient in Group 2) and 4 (the 
patient in Group 3) months. 
hyperacute rejection and renal vein thrombosis. Nine months later. 
this patient underwent cadaveric retransplantation, again ... lth 
cyclosporine-steroid therapy, with a good result for the ~ 
months of follow-up. Thus all seven patients are dialysis-free. 
Five of the six original grafts function well enough to kccp the 
serum creatinine concentration less than 2.5 mg%. The pl~th 
patient has had chronic rejection with a creatinine of 6 mg % (Tat-Ie 
ITI). 
Group Three 
Tho of the seven kidneys were rejected after three and nine 
months. Four of the five other original transplants are maintaining 
serum creatinine values of less than 2.5 mg% (Table llI). 
One of the two patients whose primary allograft was rej~ed 
under azathioprine-steroid therapy underwent retransplantatton 9 
months later with cyc1osporine-steroid therapy, and has good func-
tion three months later. Thus, six of the seven patients in the group 
are dialysis-free. 
Steroid and Insulin Requirements 
Comparison was made between Groups 2 and 3. In all patients of 
both groups the daily insulin requirements increased after trans-
plantation (fable ITI), and in a number of recipients the upward 
adjustments were striking. The greatest increases were in the 
patients treated with conventional immunosuppression. With 
almost identical average periods of follow-up, the maintenan<Ce 
doses of prednisone are almost twice as high in the azathiopriIk!-
steroid group as in the cyclosporine-steroid group (Table llI). 
Diabetic Complications 
All of the patients bearing kidneys have had a major improve-
ment in well-being. Four of the 17 patients were legally blind 
before operation (Table IT). None of the others have become blind 
since transplantation, but several have required ophthalmologic 
care, including laser treatment for detached retinae. 
A striking statistic was the frequent necessity for amputation 
(Table m. During follow-ups of 21h to 3 years, all 3 of the 
cyclosporine-steroid-treated patients in Group 1 have undergone 
unilateral below knee amputation, and one of the patients of Group 
2 has had a finger amputation. 
Three of the patients in the azathioprine-steroid series (Group .3 J 
have had amputations (Table m, one each at the great toe, trans-
metatarsal, and below knee level. 
DISCUSSION 
The value of this experience is limited by the small number of 
patients. Nevertheless, the absence of mortality, the 90% one-year 
Table III. 
Graft Function, Steroids, and Insulin Requirements in Randomized Patients Still Bearing Grafts (Mean ± SD) 
Group 
2 
3 
No. 
7' 
6" • 
Creatinine 
Mg% 
2.45 ± 1.68 
1.6 ± 0.64 
CR Range 
Mg% 
1.0 to 6.1 
0.9 to 2.8 
Daily 
Prednisone 
Mg% 
12.5 ± 3.2 
16.7 ± 2.6 
Daily Daily 
Insunn Insunn 
Preop Now 
Units Units 
32.2 ± 21.6 
44.7 ± 38.5 
51.6 ± 31.1 
79.3 ± 30.8 
"One of these patients had retransplantation 9 months ago, again under cyclosporine-steroids. 
" • One of these patients had retransplantatioA 4 months ago under cyclosporine-steroids and is receiving 20 mglday prednisone. 
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graft survival using cyclosporine-steroid therapy, the lower • 
chronic maintenance doses of prednisone, and the lower eventual 
insulin requirements are worth noting in comparison to those in the 
azathioprine-steroid group. The results in the latter series were 
acceptable, however, in that six of the seven patients are dialysis-
free. 
No matter what the immunosuppression, there were reminders 
of the difficulty of treating patients with diabetes meUitus. Even 
with relatively low maintenance doses of steroids, the insulin 
requirements invariably rose, and not uncommonly doubled or 
tripled. Ophthalmalogic problems contmued, with several patients 
requiring cataract removal or laser treatments. TIle fact that vascu-
lar disease had not been stabilized was reflected by amputation in 7 
of 17 cases. 
It seems unlikely that the patient or graft survival curves in 
diabetics will be able to match those of non-diabetic recipients as 
the years go by, unless there is perfect glucose control, an objective 
that cannot be achieved under ordinary clinical circumstances. 
Long term parity of results in diabetic and ndn-diabetic transplant 
recipients undoutedly will depend upon widespread application of 
insulin pump technology, or upon advances in pancreatic trans-
plantation. 
SUMMARY 
The courses were reviewed of seventeen type I diabetic patients 
who were treated with cadaveric renal transplantation in 1980 and 
1981, including IO who were treated with cyc!osporine-steroid 
immunosuppression, and seven who had azathioprine-steroid 
therapy. With follow-ups of I to 3 years, all I7 patients are alive, 
and 16 are dialysis-free. The results were better under cyclos-
porine-steroid therapy, but they were also acceptable under con-
ventional inununosuppression. Whatever the treatment protocol, 
there was a high incidence of continuing diabetic complications, 
including ophthalmalogic. disease and a striking need for limb or 
digit amputation. 
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